Severe Drug Allergy Physiopathology and Characterisation of Novel Diagnostic and Therapeutic Targets
FRESH-PEF5262-en
Jean-François NICOLAS
Severe Drug Allergy Physiopathology and Characterisation of Novel Diagnostic and Therapeutic Targets
SAM
FRESH-PEF5262-en
5262
FRESH-PEF5262
Jean-François NICOLAS
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Epidemiology France Portal (PEF)
HOSPICES CIVILS DE LYON (HCL)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
MINISTERE DU TRAVAIL, DE LA SANTE, DES SOLIDARITES ET DES FAMILLES
null
Jean-François;NICOLAS
Allergology
Biological determinants: Genetic predisposition
Biological determinants
To improve pathophysiological understanding of cutaneous Adverse Drug Reaction (cADRs) by clarifying the number and functional status of T lymphocytes (LT) CD8 + CTLs specific to medication. We wish to: i) confirm the involvement of CD8+ cells for different diseases; ii) understand why the same cell (CD8+) is responsible for different clinical forms of severity.
null
France
Auvergne Rhône-Alpes
Individuals
Patients population
Male
Female
Young Adult (19 to 24 years)
Adult (25 to 44 years)
Middle Aged (45 to 64 years)
Patient presenting with maculopapular rash (MPR), Drug Hypersensitivity Syndrome (DRESS) or Lyell's Syndrome (toxic epidermal necrolysis) (SJS/TEN) caused by medication, diagnosed by referring physicians in the Rhône-Alpes Auvergne Centre de Compétences (CCR2A)
Clinical data
Health event/morbidity
Health event/mortality
Health care consumption and services
Other
Through organizations (health services or institutions
schools
businesses
etc.)
< 500 individuals
Physical/biological measurements (blood pressure, weight, biochemistry, imaging, etc.)
Observational Study
Observational Study
102
Unknown
Restricted access
If other researchers wish to access this data, a request must be made and data will be made available according to good clinical practice. Filtered "access request". No "open access".
Access on specific project only